Evaluate the Possible Efficacy and Safety of Empagliflozin in Patient With Ulcerative Colitis

• It will be conducted on 60 patients having with mild to moderate degree UC divided into two groups:

• Group 1 (n=30): Patients will receive conventional treatment only (corticosteroids +immune suppressive +amino salicylic acid).
• Group 2 (n=30): Patients will receive conventional treatment (corticosteroids +immune suppressive + aminosalicylic acid) and empagliflozin (0.4 - 0.5mg/kg/day) orally (maximum dose 25mg per day).
• The patient will be selected from the Gastroenterology and Endoscopy Unit, Internal Medicine.

. All patients will be subjected to the following:

• Complete history taking.
• Colonoscopy with intubation of the ileum and biopsies of affected and unaffected areas should be obtained to confirm the diagnosis of UC.
• Blood sample collection to assess:

A) Routine Laboratory tests

• Complete blood picture (CBC).
• Liver functions (ALT, AST, Total and Direct Bilirubin).
• Kidney functions tests (Urea, serum creatinine).
• C-reactive protein.
• Fasting blood glucose.
• Urine analysis. B) Specific Laboratory tests

• Tumor necrosis factor alpha (TNF-α). 2. Adenosine monophosphate activate protein kinase (AMPK). 3. Fecal calprotectin. All patients will be assessed at baseline and after 4 months of therapy for all parameters

Inclusion criteria

•Patients with mild to moderate UC are diagnosed by history, clinical signs according to the Montreal classification of severity of ulcerative colitis and( Endoscopy, and biopsy) to establish the chronicity of inflammation and to exclude other causes of colitis.

Exclusion criteria

• Other inflammatory bowel diseases (CD).
• History of serious hypersensitivity to empagliflozin or any component of the formulation.
• Patients on dialysis.
• Severe renal impairment (eGFR <20 ml/minute/1.73m2) .
• Chronic urinary tract infection.
• Chronic genital infection.